Determinants of the access to remote specialised services provided by national sarcoma reference centres.


Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
29 May 2021
Historique:
received: 10 02 2021
accepted: 19 05 2021
entrez: 29 5 2021
pubmed: 30 5 2021
medline: 16 10 2021
Statut: epublish

Résumé

Spatial inequalities in cancer management have been evidenced by studies reporting lower quality of care or/and lower survival for patients living in remote or socially deprived areas. NETSARC+ is a national reference network implemented to improve the outcome of sarcoma patients in France since 2010, providing remote access to specialized diagnosis and Multidisciplinary Tumour Board (MTB). The IGéAS research program aims to assess the potential of this innovative organization, with remote management of cancers including rare tumours, to go through geographical barriers usually impeding the optimal management of cancer patients. Using the nationwide NETSARC+ databases, the individual, clinical and geographical determinants of the access to sarcoma-specialized diagnosis and MTB were analysed. The IGéAS cohort (n = 20,590) includes all patients living in France with first sarcoma diagnosis between 2011 and 2014. Early access was defined as specialised review performed before 30 days of sampling and as first sarcoma MTB discussion performed before the first surgery. Some clinical populations are at highest risk of initial management without access to sarcoma specialized services, such as patients with non-GIST visceral sarcoma for diagnosis [OR 1.96, 95% CI 1.78 to 2.15] and MTB discussion [OR 3.56, 95% CI 3.16 to 4.01]. Social deprivation of the municipality is not associated with early access on NETSARC+ remote services. The quintile of patients furthest away from reference centres have lower chances of early access to specialized diagnosis [OR 1.18, 95% CI 1.06 to 1.31] and MTB discussion [OR 1.24, 95% CI 1.10 to 1.40] but this influence of the distance is slight in comparison with clinical factors and previous studies on the access to cancer-specialized facilities. In the context of national organization driven by reference network, distance to reference centres slightly alters the early access to sarcoma specialized services and social deprivation has no impact on it. The reference networks' organization, designed to improve the access to specialized services and the quality of cancer management, can be considered as an interesting device to reduce social and spatial inequalities in cancer management. The potential of this organization must be confirmed by further studies, including survival analysis.

Sections du résumé

BACKGROUND BACKGROUND
Spatial inequalities in cancer management have been evidenced by studies reporting lower quality of care or/and lower survival for patients living in remote or socially deprived areas. NETSARC+ is a national reference network implemented to improve the outcome of sarcoma patients in France since 2010, providing remote access to specialized diagnosis and Multidisciplinary Tumour Board (MTB). The IGéAS research program aims to assess the potential of this innovative organization, with remote management of cancers including rare tumours, to go through geographical barriers usually impeding the optimal management of cancer patients.
METHODS METHODS
Using the nationwide NETSARC+ databases, the individual, clinical and geographical determinants of the access to sarcoma-specialized diagnosis and MTB were analysed. The IGéAS cohort (n = 20,590) includes all patients living in France with first sarcoma diagnosis between 2011 and 2014. Early access was defined as specialised review performed before 30 days of sampling and as first sarcoma MTB discussion performed before the first surgery.
RESULTS RESULTS
Some clinical populations are at highest risk of initial management without access to sarcoma specialized services, such as patients with non-GIST visceral sarcoma for diagnosis [OR 1.96, 95% CI 1.78 to 2.15] and MTB discussion [OR 3.56, 95% CI 3.16 to 4.01]. Social deprivation of the municipality is not associated with early access on NETSARC+ remote services. The quintile of patients furthest away from reference centres have lower chances of early access to specialized diagnosis [OR 1.18, 95% CI 1.06 to 1.31] and MTB discussion [OR 1.24, 95% CI 1.10 to 1.40] but this influence of the distance is slight in comparison with clinical factors and previous studies on the access to cancer-specialized facilities.
CONCLUSIONS CONCLUSIONS
In the context of national organization driven by reference network, distance to reference centres slightly alters the early access to sarcoma specialized services and social deprivation has no impact on it. The reference networks' organization, designed to improve the access to specialized services and the quality of cancer management, can be considered as an interesting device to reduce social and spatial inequalities in cancer management. The potential of this organization must be confirmed by further studies, including survival analysis.

Identifiants

pubmed: 34049529
doi: 10.1186/s12885-021-08393-4
pii: 10.1186/s12885-021-08393-4
pmc: PMC8164290
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

631

Références

Eur J Cancer. 2016 May;58:90-6
pubmed: 26974708
PLoS One. 2011;6(8):e20294
pubmed: 21826194
J Epidemiol Community Health. 2012 Nov;66(11):982-9
pubmed: 22544918
Eur J Surg Oncol. 2019 Jan;45(1):16-18
pubmed: 29685758
Cancer. 2015 Jan 1;121(1):113-22
pubmed: 25196776
Dis Colon Rectum. 2015 May;58(5):526-32
pubmed: 25850840
Acta Orthop Suppl. 2009 Apr;80(334):1-104
pubmed: 19919379
Cancer Epidemiol. 2016 Aug;43:56-62
pubmed: 27391547
Cancer. 2017 Jul 1;123(13):2516-2523
pubmed: 28241089
BMC Cancer. 2020 Mar 6;20(1):190
pubmed: 32138705
Rural Remote Health. 2008 Oct-Dec;8(4):1003
pubmed: 19012470
Ann Surg. 2016 Feb;263(2):362-8
pubmed: 25563883
Health Place. 2012 Nov;18(6):1412-21
pubmed: 22906754
Health Place. 2014 Nov;30:36-44
pubmed: 25194994
Lung Cancer. 2014 Mar;83(3):401-7
pubmed: 24491311
J Gen Intern Med. 2009 Feb;24(2):205-10
pubmed: 19067086
PLoS One. 2017 Feb 3;12(2):e0158406
pubmed: 28158190
Eur J Cancer. 2011 Nov;47(17):2493-511
pubmed: 22033323
Ann Oncol. 2019 Jul 1;30(7):1037-1038
pubmed: 31046083
BMC Cancer. 2012 Aug 13;12:351
pubmed: 22889420
Ann Oncol. 2019 Jul 1;30(7):1143-1153
pubmed: 31081028
ESMO Open. 2020 Feb;5(1):
pubmed: 32079621
Cancer. 2008 Feb 15;112(4):909-18
pubmed: 18189295
Am J Epidemiol. 2011 Oct 1;174(7):828-38
pubmed: 21836166
Health Place. 2016 Nov;42:11-18
pubmed: 27614062
Rev Epidemiol Sante Publique. 2019 Feb;67 Suppl 1:S25-S32
pubmed: 30639053
Ann Oncol. 2004 Feb;15(2):307-15
pubmed: 14760127
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv51-iv67
pubmed: 29846498
Eur J Surg Oncol. 2019 Jan;45(1):1-2
pubmed: 30041942
Int J Health Geogr. 2009 Jul 23;8:48
pubmed: 19627576
Eur J Cancer. 2006 Nov;42(17):3041-8
pubmed: 17029939
Int J Health Geogr. 2020 Nov 9;19(1):46
pubmed: 33298076
PLoS One. 2021 Feb 25;16(2):e0246958
pubmed: 33630918
Ann Oncol. 2017 Nov 1;28(11):2852-2859
pubmed: 29117335
Int J Environ Res Public Health. 2018 Oct 10;15(10):
pubmed: 30308955
Eur J Cancer. 2014 Jul;50(11):1951-6
pubmed: 24857344

Auteurs

Yohan Fayet (Y)

Equipe EMS - Département de Sciences Humaines et Sociales, Centre Léon Bérard, F-69008, Lyon, France. yohan.fayet@lyon.unicancer.fr.
Univ Lyon, Université Claude Bernard Lyon 1, Université Saint-Étienne, HESPER EA 7425, F-69008 Lyon, F-42023, Saint-Etienne, France. yohan.fayet@lyon.unicancer.fr.

Raphaël Tétreau (R)

Medical Imaging Center, Institut du Cancer, Montpellier, France.

Charles Honoré (C)

Department of Surgical Oncology, Institut Gustave Roussy, Villejuif, France.

Louis-Romée Le Nail (LR)

Department of Orthopaedic Surgery, CHU de Tours, Faculte de médecine, Université de Tours, Tours, France.

Cécile Dalban (C)

Department of Clinical Research and Innovation, Centre Léon Bérard, Lyon, France.

François Gouin (F)

Department of Surgery, Centre Léon Bérard, Lyon, France.

Sylvain Causeret (S)

Department of Surgery, Centre Georges-Francois Leclerc, Dijon, Bourgogne, France.

Sophie Piperno-Neumann (S)

Department of Medical Oncology, Institut Curie, Paris, France.

Simone Mathoulin-Pelissier (S)

Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene team, UMR 1219, F-33000, Bordeaux, France.
Clinical and Epidemiological Research Unit, INSERM CIC1401, Institut Bergonié, F-33000, Bordeaux, France.

Marie Karanian (M)

Department of Pathology, Lyon University Hospital, Lyon, France.

Antoine Italiano (A)

Department of Medical Oncology, Institut Bergonié, 33000, Bordeaux, France.

Loïc Chaigneau (L)

Department of Medical Oncology, CHRU Jean Minjoz, Besançon, France.

Justine Gantzer (J)

Department of Medical Oncology, ICANS, Strasbourg, France.

François Bertucci (F)

Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.

Mickael Ropars (M)

Orthopaedic and trauma department, Rennes1 University Pontchaillou University Hospital, Rennes, France.

Esma Saada-Bouzid (E)

Medical Oncology Department, University Côte d'Azur, Centre Antoine Lacassagne, Nice, France.

Abel Cordoba (A)

Radiation Oncology and Brachytherapy Department, Centre Oscar Lambret, Lille, France.

Jean-Christophe Ruzic (JC)

Department of Orthopaedic Surgery, Réunion University Hospital, St-Pierre, France.

Sharmini Varatharajah (S)

Surgery Department, Centre François Baclesse, F-14000, Caen, France.

Françoise Ducimetière (F)

Equipe EMS, Centre Léon Bérard, F-69008, Lyon, France.

Sylvie Chabaud (S)

Department of Clinical Research and Innovation, Centre Léon Bérard, Lyon, France.

Pascale Dubray-Longeras (P)

Oncology Department, Centre Jean Perrin, F-63011, Clermont-Ferrand, France.

Fabrice Fiorenza (F)

Department of Orthopedics Traumatology, CHU de Dupuytren, F-87042, Limoges, France.

Sixtine De Percin (S)

Medical Oncology Department, Hôpital Cochin; AP-HP, Cancer Research for PErsonalized Medicine (CARPEM); Paris University, Paris, France.

Céleste Lebbé (C)

AP-HP Dermatology Department, Saint-Louis Hospital, INSERM U976, Université de Paris Diderot, Paris, France.

Pauline Soibinet (P)

Department of Hepato-Gastroenterology and Digestive Oncology, Reims University Hospital, Reims, France.

Paul Michelin (P)

Department of Radiology and Medical Imaging, CHU-hôpitaux de Rouen, Rouen, France.

Maria Rios (M)

Department of Medical Oncology, Cancer Institute of Lorraine, Alexis Vautrin, Vandoeuvre Les Nancy, France.

Fadila Farsi (F)

CRLCC Léon Berard - Lyon, Oncology Regional Network ONCO-AURA, Lyon, France.

Nicolas Penel (N)

Lille University Medical School and Centre Oscar Lambret, Lille, France.

Emmanuelle Bompas (E)

Medical Oncology Department, ICO, Saint Herblain, Pays de la Loire, France.

Florence Duffaud (F)

Department of Medical Oncology, CHU La Timone and Aix-Marseille Université (AMU), Marseille, France.

Christine Chevreau (C)

Department of Medical Oncology, ICR IUCT- Oncopole Toulouse, Toulouse, France.

Axel Le Cesne (A)

Medical Oncology, Insitut Gustave Roussy, Villejuif, Ile-de-France, France.

Jean-Yves Blay (JY)

Departement of Medical Oncology, Centre Léon Bérard, Université de Lyon and Unicancer Paris, Lyon, France.

François Le Loarer (F)

Department of Pathology, Institut Bergonié, Bordeaux, France.

Isabelle Ray-Coquard (I)

Equipe EMS, Centre Léon Bérard, F-69008, Lyon, France.
Department of Medical Oncology, Centre Leon Berard, Lyon, Rhône-Alpes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH